Throughout the patient pathway, consideration should be given to patient eligibility and suitability for available clinical trials and discussed with individual patients as appropriate.

Author Pete Hall and Judy Fraser (on behalf of SACT subgroup) Reviewer Frances Yuille
Date of creation/update

Created 20/09/2023

Updated 09/02/2024

Version number

1.1

Review date 20/09/2026 contact nss.scottishcancernetwork@nhs.scot 
The printing of visual pathways is strongly discouraged, due to the inability to print all relevant information contained within and behind the pathways. Any user choosing to do so must acknowledge that the information may be incomplete and that essential context may be missing from a printed or reproduced pathway.

SHTG Recommendation: The use of tumour profiling tests is recommended for patients who have an intermediate risk of distant recurrence, defined using a validated tool such as PREDICT or the NPI.  Use is unlikely to provide additional benefit for decision making about adjuvant chemotherapy for patients with low or high clinical risk of distant recurrence.

 

Expand this content